

*Docket File Information*  
**SAFETY INSPECTION REPORT  
AND COMPLIANCE INSPECTION**



|  |   |   |  |
|--|---|---|--|
| 1. LICENSEE<br><b>DePaul Health Center</b><br>REPORT NUMBER(S) <b>2005-001</b> |   | 2. NRC/REGIONAL OFFICE<br><b>Region III</b>                 |  |
| 3. DOCKET NUMBER(S)<br><b>03002308</b>   | 4. LICENSE NUMBER(S)<br><b>24-02490-03</b>        | 5. DATE(S) OF INSPECTION<br><b>September 21, 2005</b>       |  |
| 6. INSPECTION PROCEDURES USED<br><b>87131, 87132</b>                           | 7. INSPECTION FOCUS AREAS<br><b>03.01 - 03.07</b> |   |  |
| <b>SUPPLEMENTAL INSPECTION INFORMATION</b>                                     |   |   |  |
| 1. PROGRAM CODE(S)<br><b>02230</b>   | 2. PRIORITY<br><b>2</b>                           | 3. LICENSEE CONTACT<br><b>Wally Fuhrman, Nuc. Med. Mgr.</b> | 4. TELEPHONE NUMBER<br><b>314/344-7671</b> |
| <input checked="checked" type="checkbox"/> Main Office Inspection              |   | Next Inspection Date: <b>September 2007</b>                 |  |
| <input type="checkbox"/> Field Office  |   |   |  |
| <input type="checkbox"/> Temporary Job Site                                    |   |   |  |

**PROGRAM SCOPE**

The licensee was a medical facility located in Bridgeton, Missouri, with authorization by the license to use byproduct materials for diagnostic and therapeutic medical procedures under 10 CFR 35.100, 35.200, 35.300, 35.400, and 35.600, at 12303 DePaul Drive, as indicated on the license.

The licensee's Nuclear Medicine Department routinely conducts an average of 35-40 administrations/scans per day for routine diagnostic, imaging, and therapeutic procedures with a staff of 4 nuclear medicine technologists at two locations within the authorized location of use. One of the locations is designated exclusively for cardiac studies. The licensee receives all licensed material as unit doses from a local nuclear pharmacy as needed. Thyroid carcinoma therapy is conducted by the oncology staff.

The radiation therapy/oncology department staff administer iodine-131 dosages up to 150 millicuries to thyroid carcinoma therapy patients who are thoroughly evaluated for release prior to each administration. No low dose brachytherapy procedures are conducted, although the licensee possesses brachytherapy cesium-137 sources which have been in storage since 2000. The licensee possesses one Nucletron Microselectron HDR afterloader unit and sources are exchanged three times per year by Nucletron service engineers. The device is used, stored, and secured, in a linac treatment room. Treatment procedures of 3-5 fractions average one patient per month.

**Performance Observations**

During the inspection, the licensee's available staff demonstrated/discussed: (1) survey instruments and required surveys; (2) package receipt and check-in procedures; (3) radiopharmaceutical therapy dosage prep; (4) wipe test counting; (5) dosimetry; (6) brachytherapy written directives; (7) waste handling; (8) sealed source inventories; (9) routine security of licensed material; (10) I-131 procedures and written directives; (11) electrometer calibrations; (12) HDR calibrations and output checks; (13) HDR daily checks performed prior to each administered fraction; (14) HDR emergency tools; (15) radiation safety program audit results.